Last $10.21 USD
Change Today +0.19 / 1.90%
Volume 606.1K
DYAX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

dyax corp (DYAX) Snapshot

Open
$10.05
Previous Close
$10.02
Day High
$10.22
Day Low
$9.91
52 Week High
02/26/14 - $10.99
52 Week Low
09/3/13 - $4.50
Market Cap
1.4B
Average Volume 10 Days
782.2K
EPS TTM
$-0.15
Shares Outstanding
136.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DYAX CORP (DYAX)

dyax corp (DYAX) Related Bloomberg News

View More Bloomberg News

dyax corp (DYAX) Related Businessweek News

No Related Businessweek News Found

dyax corp (DYAX) Details

Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and plasma kallikrein-mediated (PKM) angioedemas. The company offers KALBITOR for the treatment of acute attacks of HAE. It is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein, which would be a candidate to prophylactically treat HAE and other PKM disorders. The company distributes KALBITOR through a network of wholesale and specialty pharmacy arrangements. It has agreements with CVie Therapeutics for the development and commercialization of KALBITOR in the treatment of HAE and other angioedema indications in China; and Novellus Biopharma AG for the development and commercialization of KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. The company also has a strategic collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in Europe, North Africa, the Middle East, and Russia. Dyax Corp. was founded in 1989 and is headquartered in Burlington, Massachusetts.

120 Employees
Last Reported Date: 03/3/14
Founded in 1989

dyax corp (DYAX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $615.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $409.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $444.0K
Executive Vice President and General Counsel
Total Annual Compensation: $360.0K
Consultant
Total Annual Compensation: $148.7K
Compensation as of Fiscal Year 2013.

dyax corp (DYAX) Key Developments

Dyax Corp. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Revenue Guidance for the Year 2014

Dyax Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenues, net were $19,585,000 compared to $11,336,000 a year ago. Loss from operations was $411,000 compared to $5,850,000 a year ago. Net loss was $3,061,000 compared to $8,432,000 a year ago. Basic and diluted net loss per share was $0.02 compared to $0.08 a year ago. For the six months, the company's total revenues, net was $33,702,000 compared to $23,376,000 a year ago. Loss from operations was $3,437,000 compared to $14,313,000 a year ago. Net loss was $8,772,000 compared to $19,625,000 a year ago. Basic and diluted net loss per share was $0.07 compared to $0.19 a year ago. The company has revised its financial guidance for 2014: Top-line total revenue expected to be in the range of $61 million to $66 million, including KALBITOR net sales of $51 million to $56 million. Revised guidance reflects the expectations that quarterly and annual KALBITOR net sales will fluctuate due to the level of KALBITOR utilization for individual patients. Utilization continues to vary significantly based on fluctuations in the number of HAE attacks and the consistency with which patients treat their HAE attacks with KALBITOR.

Dyax Corp. to Report Q2, 2014 Results on Jul 29, 2014

Dyax Corp. announced that they will report Q2, 2014 results at 5:00 PM, US Eastern Standard Time on Jul 29, 2014

Dyax Corp., Q2 2014 Earnings Call, Jul 29, 2014

Dyax Corp., Q2 2014 Earnings Call, Jul 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAX:US $10.21 USD +0.19

DYAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €8.50 EUR 0.00
BioCryst Pharmaceuticals Inc $13.50 USD +0.29
Genmab A/S kr224.60 DKK -1.70
Pharming Group NV €0.41 EUR -0.002
XOMA Corp $4.38 USD +0.02
View Industry Companies
 

Industry Analysis

DYAX

Industry Average

Valuation DYAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.6x
Price/Book 13.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYAX CORP, please visit www.dyax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.